INVO Fertility, Inc. IVF
Annual Report on Form 10-K should be read together and in connection with the other reports that have been filed by us with the SEC for
a comprehensive description of our financial condition and operating results. In the interest of disclosure, we have included in this
Form 10-K certain material events and developments that have taken place through the date of filing of this Form 10-K with the SEC.
this Annual Report on Form 10-K, INVO Fertility, Inc., (INVO Fertility, Inc., together with its subsidiaries, is referred to in this
Last close
0.57
2026-10-23
Market cap
$1.4M
2026-06-30 share count
52-week range
0.51 - 26.58
Valuation FY2025 figures against the last close
P/S0.2x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-214.64
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $6.5M | $3.0M | $822.2K | $4.2M | $1.0M | $1.5M | $494.4K | $282.1K | $50.9K |
| Cost of revenue | $30.6K | $12.2K | $2.0M | $331.5K | $145.1K | $88.8K | $139.7K | $90.4K | $52.0K | $15.1K |
| Gross profit | $6.8M | $6.5M | $1.0M | $490.7K | $4.0M | $948.5K | $1.3M | $404.0K | $230.2K | $35.8K |
| R&D | — | $4.9K | $165.9K | $544.0K | $216.4K | $398.4K | $0 | — | — | — |
| SG&A | $7.7M | $8.1M | $7.5M | $10.0M | $9.0M | $6.1M | $3.1M | $3.0M | $870.6K | $2.1M |
| Total operating expenses | $14.1M | $13.2M | $9.8M | $11.4M | $9.2M | $6.5M | $3.1M | $3.0M | $870.6K | $2.1M |
| Operating income | -$7.2M | -$6.6M | -$6.8M | -$10.6M | -$5.2M | -$5.5M | -$1.8M | -$2.6M | -$640.4K | -$2.1M |
| Interest expense | $1.3M | $1.0M | $925.9K | $59.4K | $1.3M | $2.8M | $387.6K | $442.0K | $20.9K | $13.8K |
| Pre-tax income | -$5.5M | -$7.6M | -$8.0M | -$10.9M | -$6.7M | -$8.3M | -$2.2M | -$3.1M | -$702.2K | -$2.1M |
| Income tax | $150.4K | $140.2K | $27.8K | $2.9K | $4.8K | $36 | $433 | $0 | $1.7M | $0 |
| Net income | $23.3M | $9.1M | $8.0M | -$10.9M | -$6.7M | -$8.3M | -$2.2M | -$3.1M | -$702.2K | -$2.1M |
| EPS, basic | -214.64 | -3,782.65 | -67.37 | -17.97 | -0.63 | -1.52 | -0.45 | -0.02 | 0.00 | -0.02 |
| EPS, diluted | -214.64 | -3,782.65 | -67.37 | -17.97 | -0.63 | -1.52 | -0.45 | -0.02 | 0.00 | -0.02 |
| Shares, diluted (wtd. avg.) | 117,083 | 2,514 | 119,264 | 606,130 | 10.6M | 5.5M | 4.9M | 147.3M | 141.3M | 139.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | $5.7M | $10.1M | $1.2M | $212.2K | $25.8K | $152.4K |
| Receivables | $217.3K | $113.1K | $140.6K | $77.1K | $50.5K | $21.7K | $7.6K | $225.9K | $86.7K | $2.8K |
| Inventory | $225.3K | $219.8K | $264.5K | $263.6K | $287.8K | $265.4K | $101.4K | $43.5K | $58.9K | $85.2K |
| Total current assets | $2.8M | $1.3M | $1.3M | $621.1K | $6.3M | $10.5M | $1.5M | $731.1K | $234.4K | $251.4K |
| Property, plant and equipment | $386.2K | $466.7K | $826.4K | $436.7K | $501.4K | $132.2K | $93.1K | $34.4K | $15.7K | $15.7K |
| Goodwill | $5.9M | $5.9M | $5.9M | — | — | — | — | — | — | — |
| Other intangibles | $1.3M | $3.3M | $4.1M | — | $132.1K | $95.0K | $7.2K | $11.8K | $16.3K | $19.1K |
| Total assets | $20.2M | $46.1M | $18.5M | $6.0M | $9.5M | $10.9M | $1.8M | $777.3K | $266.4K | $286.2K |
| Accounts payable | $2.0M | $3.1M | $2.3M | $1.3M | $443.4K | $328.9K | $371.5K | $571.8K | $960.7K | $974.9K |
| Short-term debt | $1.3M | $6.3M | — | — | — | — | — | — | — | — |
| Total current liabilities | $12.1M | $17.9M | $8.0M | $1.2M | $1.7M | $2.3M | $1.5M | $3.5M | $5.1M | $4.8M |
| Long-term debt | $744.7K | $1.1M | — | — | — | — | — | — | — | — |
| Total liabilities | $16.2M | $26.0M | $17.6M | $2.6M | $5.2M | $5.2M | $5.5M | $3.5M | $5.3M | $4.9M |
| Retained earnings | -$88.5M | -$67.3M | -$57.8M | -$49.8M | -$38.9M | -$32.2M | -$23.9M | -$21.7M | -$18.6M | -$17.9M |
| Total equity | -$7.0M | $12.6M | $892.8K | -$977.6K | $7.3M | $5.7M | -$3.7M | -$2.7M | -$5.0M | -$4.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$3.0M | -$4.8M | -$6.6M | -$6.0M | -$4.8M | $1.4M | -$653.0K | -$181.3K | -$323.9K |
| Depreciation and amortisation | $677.4K | $919.6K | $200.9K | $77.3K | $27.8K | $11.9K | $10.8K | $5.2K | $2.8K | $1.9K |
| Stock-based compensation | $162.9K | — | — | $1.6M | $1.5M | $1.1M | $69.8K | $0 | — | — |
| Capital expenditure | $43.4K | $183.7K | $444.7K | $10.8K | $415.7K | $49.3K | $64.8K | $19.4K | $0 | $15.7K |
| Investing cash flow | -$2.7M | $363.9K | -$2.5M | -$81.2K | -$2.2M | -$187.3K | -$114.7K | -$19.4K | $0 | -$15.7K |
| Financing cash flow | $11.1M | $3.1M | $7.4M | $1.1M | $3.8M | $13.8M | -$229.5K | $858.9K | $54.6K | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-029785.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.9K | $282.1K | $494.4K | $1.5M | $1.0M | $4.2M | $822.2K | $3.0M | $6.5M | $6.8M |
| Gross profit | $35.8K | $230.2K | $404.0K | $1.3M | $948.5K | $4.0M | $490.7K | $1.0M | $6.5M | $6.8M |
| Net income | -$2.1M | -$702.2K | -$3.1M | -$2.2M | -$8.3M | -$6.7M | -$10.9M | $8.0M | $9.1M | $23.3M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |